Updates ·
Health notices · Thursday 29 October
3 notices from the agencies today, in plain words, each with the original linked.
FDA class II warning for certain sterile eye drops
FDA · Recall
If you use “Sterile Eye Drops Advanced Relief” products (sold under multiple brand names listed in the notice), the US Food and Drug Administration reports a class II issue: lack of assurance of sterility.
“Sterile” means free from germs. If sterility can’t be assured, using the eye drops could increase the risk of eye infection.
The notice was published 2026-10-14 and covers distribution across the US nationwide under the specific product and bottle details described.
Eye drops recalled for lack of sterility assurance
FDA · Recall
If you use certain “Sterile High Performance Ultra Lubricating Eye Drops” (polyethylene glycol 400, 0.4%) for dry, irritated eyes, the FDA notice describes a lack of assurance of sterility.
Because sterility is not assured, the product may pose a risk of infection in or around the eye.
This notice applies to specific listed brands/sellers distributed nationwide in the US, published October 14, 2026.
FDA approves Namzaric for moderate to severe Alzheimer’s dementia
FDA · Approval
If you have moderate to severe Alzheimer’s dementia, the FDA has approved Namzaric (memantine hydrochloride and donepezil hydrochloride).
Namzaric combines two medicines: memantine, which works as an NMDA receptor antagonist, and donepezil, which helps by inhibiting acetylcholinesterase.
It is indicated for people with Alzheimer’s dementia who are already stabilized on donepezil hydrochloride; the approval means this combination is now an option for treatment.